Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Terminal complement inhibition is the standard of care for atypical hemolytic uremic syndrome (aHUS). The optimal duration of complement inhibition is unknown, although indefinite therapy is common. Here, we present the outcomes of a physician-directed eculizumab discontinuation and monitoring proto...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Chaturvedi, Shruti, Dhaliwal, Noor, Hussain, Sarah, Dane, Kathryn, Upreti, Harshvardhan, Braunstein, Evan M., Yuan, Xuan, Sperati, C. John, Moliterno, Alison R., Brodsky, Robert A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2021
Konular:
Thrombosis and Hemostasis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948299/
https://ncbi.nlm.nih.gov/pubmed/33683339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003175
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller